Bukwang Pharmaceutical Co., Ltd. (003000) AI Stock Analysis

Bukwang Pharmaceutical Co., Ltd.

(Korea Exchange:003000)

Select Model

Rating:50Neutral

Price Target:KRW 3,755.00▲(2.32% Upside)

Action:initiatedcoverage

Date:10/28/26

The score is held back primarily by weak TTM cash generation (negative free cash flow and poor cash conversion) and deteriorating margins despite a return to revenue growth and profitability. Technicals add pressure with the stock trading below key moving averages and negative MACD. Valuation is also a headwind due to a high P/E, partially offset by a ~3.33% dividend yield.

Positive Factors

Returning revenue growthThe return to 7.18% TTM revenue growth indicates that Bukwang is regaining commercial momentum after earlier volatility. Sustained sales expansion can strengthen operating scale, support product commercialization, and provide a foundation for rebuilding profitability over the coming quarters.

Negative Factors

Weak cash generationVery low operating cash flow and negative TTM free cash flow show that reported earnings are not currently converting into sufficient cash. If this persists, Bukwang may have less flexibility to fund development, commercialization, or other investments without relying on additional financing.

Bukwang Pharmaceutical Co., Ltd. (003000) vs. SPDR S&P 500 ETF (SPY)

Market Cap: KRW 362.10B
Dividend Yield: 3.41%
Average Volume (3M): 417.71K
Price to Earnings (P/E): 63.5
Beta (1Y): 0.06
Revenue Growth: 22.17%
EPS Growth: -38.54%
Country: KR
Employees: 650
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Bukwang Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids, in...

Bukwang Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Revenue returned to growth (TTM +7.18%) and the company is back to positive operating profit and net income, but margin compression (net margin ~6.3% in 2025 to ~3.7% TTM) and a sharp cash-flow deterioration (very low operating cash flow and negative free cash flow in TTM) materially weaken overall financial quality. Balance sheet leverage is manageable (debt-to-equity ~0.24), but ROE remains low.

Income Statement

61Positive

Balance Sheet

74Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	215.09B	200.71B	160.09B	125.93B	190.91B	182.49B
Gross Profit	98.70B	95.72B	74.34B	50.05B	79.43B	75.76B
EBITDA	16.75B	19.65B	7.63B	-31.47B	4.89B	11.40B
Net Income	8.91B	12.57B	-2.64B	-31.33B	-2.47B	-916.62M
Balance Sheet
Total Assets	467.05B	502.17B	373.18B	429.02B	400.93B	397.42B
Cash, Cash Equivalents and Short-Term Investments	169.10B	216.21B	130.09B	151.23B	85.52B	84.28B
Total Debt	80.67B	80.34B	79.42B	79.39B	930.79M	1.56B
Total Liabilities	132.66B	161.24B	129.03B	194.75B	129.08B	117.36B
Stockholders Equity	334.13B	341.46B	243.68B	226.31B	263.22B	269.61B
Cash Flow
Free Cash Flow	-4.45B	11.15B	31.75B	-13.32B	11.47B	25.74B
Operating Cash Flow	3.39B	18.48B	34.36B	-10.50B	16.46B	26.52B
Investing Cash Flow	-50.38B	-95.68B	-27.73B	-2.32B	-3.15B	4.75B
Financing Cash Flow	74.53B	82.76B	-67.65B	76.84B	-10.40B	-27.48B

Bukwang Pharmaceutical Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price3670.00

Price Trends

50DMA4004.70Negative

100DMA4079.00Negative

200DMA4889.00Negative

Market Momentum

MACD-89.30Positive

RSI38.47Neutral

STOCH18.46Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003000, the sentiment is Negative. The current price of 3670.00 is below the 20-day moving average (MA) of 3896.25, below the 50-day MA of 4004.70, and below the 200-day MA of 4889.00, indicating a bearish trend. The MACD of -89.30 indicates Positive momentum. The RSI at 38.47 is Neutral, neither overbought nor oversold. The STOCH value of 18.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003000.

Bukwang Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:003000 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KR:001060	71Outperform	KRW 555.42B	5.49	―	2.83%	10.50%	96.29%
KR:249420	60Neutral	KRW 397.78B	8.87	―	1.59%	-0.65%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:009290	52Neutral	KRW 293.53B	12.35	―	1.60%	5.50%	-26.11%
KR:019170	51Neutral	KRW 429.50B	-874.35	―	―	6.21%	95.65%
KR:003000	50Neutral	KRW 362.10B	63.51	―	3.41%	22.17%	-38.54%
KR:170900	46Neutral	KRW 322.72B	-55.36	―	2.07%	15.38%	―

* General Sector Average

Performance Comparison

KR:003000 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:003000	Bukwang Pharmaceutical Co., Ltd.	3670.00	102.22	2.87%
KR:001060	JW Pharmaceutical Corporation	23000.00	-645.26	-2.73%
KR:009290	Kwang Dong Pharmaceutical Co., Ltd.	6240.00	605.59	10.75%
KR:019170	Shinpoong Pharmaceutical Co., Ltd.	8350.00	-4980.00	-37.36%
KR:170900	Dong-A ST Co., Ltd.	33850.00	-12411.18	-26.83%
KR:249420	Ildong Pharmaceutical Co., Ltd.	12580.00	-14837.52	-54.12%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Bukwang Pharmaceutical Co., Ltd. AI Stock Analysis